Cellivery Therapeutics Inc
KOSDAQ:268600
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
N/A
N/A
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Cellivery Therapeutics Inc
Total Receivables
Cellivery Therapeutics Inc
Total Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
C
|
Cellivery Therapeutics Inc
KOSDAQ:268600
|
Total Receivables
₩1.8B
|
CAGR 3-Years
68%
|
CAGR 5-Years
35%
|
CAGR 10-Years
N/A
|
|
|
Samsung Biologics Co Ltd
KRX:207940
|
Total Receivables
₩1T
|
CAGR 3-Years
40%
|
CAGR 5-Years
60%
|
CAGR 10-Years
N/A
|
|
|
K
|
Knotus Co Ltd
KOSDAQ:278650
|
Total Receivables
₩6.6B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
|
|
S
|
ST Pharm Co Ltd
KOSDAQ:237690
|
Total Receivables
₩122.6B
|
CAGR 3-Years
39%
|
CAGR 5-Years
47%
|
CAGR 10-Years
N/A
|
|
|
F
|
FutureChem Co Ltd
KOSDAQ:220100
|
Total Receivables
₩3.6B
|
CAGR 3-Years
8%
|
CAGR 5-Years
5%
|
CAGR 10-Years
N/A
|
|
|
L
|
LegoChem Biosciences Inc
KOSDAQ:141080
|
Total Receivables
₩20.9B
|
CAGR 3-Years
-32%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
80%
|
|
Cellivery Therapeutics Inc
Glance View
Cellivery Therapeutics, Inc. engages in the research and development of medicine and pharmacy. The company is headquartered in Seoul, Seoul. The company went IPO on 2018-11-09. The firm develops biotherapeutics capable of entering cells in vivo through proprietary therapeuticmolecule systemic delivery technology (TSDT). The firm research and develop therapeutic drug candidates such as Parkinson’s disease treatment, pancreatic cancer and solid cancer treatment, bone formation promoter, as well as advanced obesity & type II diabetes mellitus; new drugs for research including DNA recombinase and reprogramming factors (RFs).
See Also
What is Cellivery Therapeutics Inc's Total Receivables?
Total Receivables
1.8B
KRW
Based on the financial report for Jun 30, 2024, Cellivery Therapeutics Inc's Total Receivables amounts to 1.8B KRW.
What is Cellivery Therapeutics Inc's Total Receivables growth rate?
Total Receivables CAGR 5Y
35%
Over the last year, the Total Receivables growth was -36%. The average annual Total Receivables growth rates for Cellivery Therapeutics Inc have been 68% over the past three years , 35% over the past five years .
You don't have any saved screeners yet
